A phase 1/2, partially randomized, open-label study of visilizumab in patients with severe ulcerative colitis refractory to intravenous corticosteroids.
Phase of Trial: Phase I/II
Latest Information Update: 08 Mar 2012
At a glance
- Drugs Visilizumab (Primary)
- Indications Ulcerative colitis
- Focus Adverse reactions; Therapeutic Use
- Sponsors PDL BioPharma
- 08 Mar 2012 Actual end date (Dec 2006) added as reported by ClinicalTrials.gov.
- 01 Apr 2010 Results published in Inflammatory Bowel Disease.
- 26 Sep 2009 New trial record.